AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis First-in-class, peripheral serotonin (5-HT2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE...